News
For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...
1h
NewsNation on MSNWeight loss drugs may lower risk of dementia, stroke: StudyBenefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.
18h
The Brighterside of News on MSNWeight-loss drug Tirzepatide significantly slows breast cancer growth, study findsKey Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.
1d
New Scientist on MSNYou don't need to take drugs like Ozempic consistently to lose weightPeople who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...
There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...
Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...
New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone ...
WEIGHT loss jabs could boost men’s sex lives, a study suggests. Research found injections like Wegovy and Mounjaro can raise ...
Popular weight loss medications like Ozempic can help reverse low testosterone levels in men with obesity or Type 2 diabetes, ...
A new study suggests that eating more protein while taking GLP-1 medications could help prevent muscle loss, a common side ...
Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...
The brain busting side-effects of Ozempic-like fat jabs revealed – ‘slashing risk of silent killers’
THEY’VE been hailed as miracle weight-loss jabs – but the effects of Ozempic-style drugs could go far beyond the waistline. New research suggests these so-called “skinny pens” may also ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results